|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
3.750 +0.020 (+0.536%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 28,866,159 | 10.179% | 26,199,409 | 28,780,412 | 26,861,356 | 23,647,224 |
| Cost of Sales | (5,336,218) | 6.941% | (4,989,877) | (5,795,510) | (5,332,095) | (5,182,320) |
| Gross Profit | 23,529,941 | 10.940% | 21,209,532 | 22,984,902 | 21,529,261 | 18,464,904 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (118,299) | -77.497% | (525,710) | (152,976) | 13,630,790 | (3,233) | |
| Profit / (Loss) before Taxation | 5,277,468 | -2.448% | 5,409,906 | 5,778,604 | 18,572,673 | 5,013,044 | |
| Taxation | (492,918) | -38.174% | (797,267) | (775,986) | (1,957,880) | (672,377) | |
| Profit / (Loss) from Discontinued Operations | 1,580,132 | 225.962% | 484,759 | -- | -- | -- | |
| Non-controlling Interests | (2,864,848) | 3.594% | (2,765,459) | (2,459,048) | (2,006,381) | (1,569,581) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,499,834 | 50.083% | 2,331,939 | 2,543,570 | 14,608,412 | 2,771,086 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (204,447) | -- | 116,902 | 237,617 | 146,560 | 129,365 |
| Depreciation & Amortisation | 1,321,181 | 27.442% | 1,036,695 | 1,046,984 | 992,556 | 1,654,836 |
| Directors' Emoluments | -- | -- | 203,407 | 227,139 | 176,656 | 170,783 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 19.130 | 51.946% | 12.590 | 13.660 | 77.830 | 14.740 |
| DPS (cts) | 6.530 | -- | 4.534 | 10.505 | 6.488 | 6.141 |
| Dividend Payout Ratio (%) | 34.134% | -- | 36.015% | 76.904% | 8.336% | 41.664% |
| Cash flow per share ($) | -- | -- | 0.327 | 0.336 | 0.286 | 0.283 |
| NBV per share ($) | 1.701 | -- | 1.621 | 1.581 | 1.608 | 0.888 |
| Remarks: | Real time quote last updated: 31/03/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,499,834 |
| %Change | 50.083% |
| EPS / (LPS) | RMB 0.191 |
| NBV Per Share (¥) | RMB 1.701 |